Results 151 to 160 of about 3,797 (192)

Simeprevir/sofosbuvir

Reactions Weekly, 2016
  +9 more sources

Simeprevir: First Global Approval

Drugs, 2013
Simeprevir (Sovriad(TM)) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).
Asha, Vaidya, Caroline M, Perry
openaire   +2 more sources

Simeprevir/sofosbuvir

Reactions Weekly, 2015
  +7 more sources

Simeprevir

Reactions Weekly, 2015
  +4 more sources

Simeprevir

Reactions Weekly, 2017
  +4 more sources

Simeprevir

Reactions Weekly, 2016
  +4 more sources

Simeprevir/sofosbuvir

Reactions Weekly, 2017
  +5 more sources

Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice

International Journal of Antimicrobial Agents, 2022
Hang Yang, Jin He, Hongping Wei
exaly  

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022
Sherif Ramzy, Ahmed Hussien
exaly  

Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M pro

Journal of Biomolecular Structure and Dynamics, 2022
Abhithaj J, Dileep Francis, C Sadasivan   +2 more
exaly